Clinical Trials Directory

Trials / Completed

CompletedNCT04334577

Study on Efficacy of Attenuated Zoster Vaccine, Live

Evaluation of the Efficacy of Attenuated Zoster Vaccine, Live From Herpes Zoster in Adults Aged 40 Years or older---a Multicenter, Randomized, Double-blinded,Placebo-controlled Trial Phase III

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
25,000 (actual)
Sponsor
Changchun BCHT Biotechnology Co. · Industry
Sex
All
Age
40 Years
Healthy volunteers
Accepted

Summary

Varicella-zoster virus (VZV) is a herpesvirus that causes two distinct clinical syndromes. Primary infection is manifested as varicella (chickenpox) , whereas reactivation of latent VZV results in a localized eruption known as herpes zoster. The investigational vaccine of this study is produced by Changchun BCHT biotechnology Co. It's a live attenuated herpes zoster vaccine based on the production process of live attenuated chickenpox vaccine.This study plans to have 25000 adults aged 40 years or older and involves in a randomized, double-blind, placebo-controlled trial . The primary outcome is to evaluate the efficacy of the vaccine against herpes zoster 30 days after vaccination and the safety of the vaccine.

Detailed description

Varicella-zoster virus (VZV) is a herpesvirus that causes two distinct clinical syndromes. Primary infection is manifested as varicella (chickenpox) , whereas reactivation of latent VZV results in a localized eruption known as herpes zoster. The investigational vaccine of this study is produced by Changchun BCHT biotechnology Co. It's a live attenuated herpes zoster vaccine based on the production process of live attenuated chickenpox vaccine.This study plans to have 25000 adults aged 40 years or older and involves in a randomized, double-blind, placebo-controlled trial . The primary outcome is to evaluate the efficacy of the vaccine against herpes zoster 30 days after vaccination and the safety of the vaccine.

Conditions

Interventions

TypeNameDescription
BIOLOGICALlive attenuated zoster vaccinesubcutaneous injection
BIOLOGICALplacebosubcutaneous injection

Timeline

Start date
2020-04-20
Primary completion
2021-07-18
Completion
2021-07-18
First posted
2020-04-06
Last updated
2021-12-08

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT04334577. Inclusion in this directory is not an endorsement.